Topic: Psoriasis

DermWireTV: Doximity Physician Compensation Report, EADV Updates, PsO in the Know

Series: DermWire TV | November 5, 2020

Doximity’s fourth annual Physician Compensation Report shows a widening of the gender pay gap. From biologics and investigational molecules for psoriasis to socks to prevent foot odors, the European Academy of Dermatology and Venereology annual meeting highlights emerging therapies for dermatology patients. Chef Aarón Sánchez uses his personal experience with psoriasis to raise awareness of the condition and encourage open dialogue among those affected by it.

Watch Video

DermWireTV: Cassiopeia Winlevi; Psoriasis Guidelines; Cyndi Lauper's PsO in the Know; Sarah Michelle Gellar's CoolSculpting

Series: DermWire TV | September 10, 2020

The FDA has approved Winlevi (Clascoterone cream 1%) from Cassiopea for the treatment of acne in patients 12 years and older.New Guidelines of care for the Management of Psoriasis with Systemic Nonbiologic Therapies, jointly issued by the American Academy of Dermatology and the National Psoriasis Foundation, cover a total of 12 non-biologic systemic treatments used—many off-label—for the treatment of psoriasis. Singer, songwriter, actress, and activist Cyndi Lauperhosts “PsO in the Know,” a new podcast series highlighting the impact of psoriasis. Sarah Michelle Gellar is the international ambassador for CoolSculpting in partnership withAllergan Aesthetics, an AbbVie company.

Watch Video

DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates

Series: DermWire TV | July 30, 2020

The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of Dermatology's Climate Change Committee. FDA has approved MC2 Therapeutics Wynzora Cream for once-daily topical treatment of plaque psoriasis in adults. Tremfya is the first IL-23 inhibitor FDA-approved for active psoriatic arthritis. AbbVie's upadacitinib met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis.

Watch Video

What Skincare Products are Best for Psoriasis?

Series: Ask Dr. Friedman | July 1, 2020

Not many topical formulations tout benefits for psoriasis, but that doesn't mean there are no useful products. Dr. Friedman offers his take.

Watch Video

DermWireTV: COVID-19 Loans, Taltz for Peds, Finacea Returns

Series: DermWire TV | April 16, 2020

SBA Loans and Paycheck Protection Program (PPP) loans for practices impacted by the coronavirus pandemic are among the options addressed in a new video series, “Coping with COVID-19.” Eli Lilly and Company's Taltz is now approved to manage moderate to severe plaque psoriasis in pediatric patients ages 6 to under 18. LEO Pharma’s Finacea Foam (azelaic acid 15%) is back in pharmacies—just in time for Rosacea Awareness Month.